Abstract
OPINION article Front. Immunol., 12 January 2015Sec. Inflammation Volume 5 - 2014 | https://doi.org/10.3389/fimmu.2014.00685
Highlights
Tumor heterogeneity has been recognized as one of the main factors for cancer therapy failure, and has just started to be dissected using next-generation sequencing (NGS) approaches [4]
NGS-derived studies have often been conducted using single fragments/biopsies of primary tumors, and fail to reflect the global tumor heterogeneity, dynamics, and drug sensitivities, likely to change during tumor evolution and treatment
Most of these have been focused on the characterization of the cargo of extracellular vesicles (EVs) in different types of cancer, using either conditioned media of cancer cell lines, or unique samples from cancer patients’ body fluids
Summary
Tumor heterogeneity has been recognized as one of the main factors for cancer therapy failure, and has just started to be dissected using next-generation sequencing (NGS) approaches [4]. EVs can be detected in biological fluids such as plasma, serum, ascites, or urine, and provide excellent minimally invasive biomarker candidates to monitor cancer patients’ progression, prognosis, and treatment efficacy [10, 11].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
